Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations

Laurie L. Ackerman, Kenneth A. Follett, Richard W. Rosenquist

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

To evaluate the effectiveness of intrathecal clonidine or clonidine/opioid admixture for the treatment of chronic pain states, a retrospective chart audit of 15 patients seen by the Pain Medicine and Neurosurgical Services was performed. Subjects included 9 men and 6 women aged 26-86 years. Diagnoses included complex regional pain syndrome, neuropathic pain, and cancer pain. All patients received a trial of single-shot and/or short-term infusion of clonidine. Those reporting a significant reduction in pain, or at least 50% reduction in their visual analog scale (VAS), received long-term therapy. Intrathecal clonidine as a single-shot dose, infusion, or as intrathecal polytherapy did not improve VAS scales from pre-treatment values in 5 patients. Ten patients reported significant pain relief or >50% decrease in VAS scores with the initial trial and received long-term therapy. Two received clonidine alone for 7-11 months before the therapy failed; others failed after just a few days. Seven of eight initially responded to clonidine alone (75-950 μg/day) before failing and requiring a second drug. Three received hydromorphone (200-8000 μg/day) and four morphine (0.15-15 mg/day) with clonidine. Four patients then failed 2-drug therapy (duration 6-21 months). Two continue with intrathecal clonidine/hydromorphone (duration 19-29 months) and 1 with clonidine/morphine (duration 21 months). After initiation of intrathecal clonidine, one patient reported good relief with clonidine/morphine until his death 5 months later. In this population, intrathecal clonidine was of limited utility for most patients. It may be of benefit for subset(s) of patients, but in our experience, duration of relief is typically <18 months.

Original languageEnglish (US)
Pages (from-to)668-677
Number of pages10
JournalJournal of Pain and Symptom Management
Volume26
Issue number1
DOIs
StatePublished - Jul 1 2003

Fingerprint

Clonidine
Chronic Pain
Opioid Analgesics
Visual Analog Scale
Hydromorphone
Morphine
Pain
Complex Regional Pain Syndromes
Therapeutics
Neuralgia
Medicine

Keywords

  • Chronic pain
  • Clonidine
  • Intrathecal
  • Opioids
  • Polyanalgesia

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. / Ackerman, Laurie L.; Follett, Kenneth A.; Rosenquist, Richard W.

In: Journal of Pain and Symptom Management, Vol. 26, No. 1, 01.07.2003, p. 668-677.

Research output: Contribution to journalArticle

@article{fd7298d7e3a34c07a20ab0ab5c0c997e,
title = "Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations",
abstract = "To evaluate the effectiveness of intrathecal clonidine or clonidine/opioid admixture for the treatment of chronic pain states, a retrospective chart audit of 15 patients seen by the Pain Medicine and Neurosurgical Services was performed. Subjects included 9 men and 6 women aged 26-86 years. Diagnoses included complex regional pain syndrome, neuropathic pain, and cancer pain. All patients received a trial of single-shot and/or short-term infusion of clonidine. Those reporting a significant reduction in pain, or at least 50{\%} reduction in their visual analog scale (VAS), received long-term therapy. Intrathecal clonidine as a single-shot dose, infusion, or as intrathecal polytherapy did not improve VAS scales from pre-treatment values in 5 patients. Ten patients reported significant pain relief or >50{\%} decrease in VAS scores with the initial trial and received long-term therapy. Two received clonidine alone for 7-11 months before the therapy failed; others failed after just a few days. Seven of eight initially responded to clonidine alone (75-950 μg/day) before failing and requiring a second drug. Three received hydromorphone (200-8000 μg/day) and four morphine (0.15-15 mg/day) with clonidine. Four patients then failed 2-drug therapy (duration 6-21 months). Two continue with intrathecal clonidine/hydromorphone (duration 19-29 months) and 1 with clonidine/morphine (duration 21 months). After initiation of intrathecal clonidine, one patient reported good relief with clonidine/morphine until his death 5 months later. In this population, intrathecal clonidine was of limited utility for most patients. It may be of benefit for subset(s) of patients, but in our experience, duration of relief is typically <18 months.",
keywords = "Chronic pain, Clonidine, Intrathecal, Opioids, Polyanalgesia",
author = "Ackerman, {Laurie L.} and Follett, {Kenneth A.} and Rosenquist, {Richard W.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0885-3924(03)00144-1",
language = "English (US)",
volume = "26",
pages = "668--677",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations

AU - Ackerman, Laurie L.

AU - Follett, Kenneth A.

AU - Rosenquist, Richard W.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - To evaluate the effectiveness of intrathecal clonidine or clonidine/opioid admixture for the treatment of chronic pain states, a retrospective chart audit of 15 patients seen by the Pain Medicine and Neurosurgical Services was performed. Subjects included 9 men and 6 women aged 26-86 years. Diagnoses included complex regional pain syndrome, neuropathic pain, and cancer pain. All patients received a trial of single-shot and/or short-term infusion of clonidine. Those reporting a significant reduction in pain, or at least 50% reduction in their visual analog scale (VAS), received long-term therapy. Intrathecal clonidine as a single-shot dose, infusion, or as intrathecal polytherapy did not improve VAS scales from pre-treatment values in 5 patients. Ten patients reported significant pain relief or >50% decrease in VAS scores with the initial trial and received long-term therapy. Two received clonidine alone for 7-11 months before the therapy failed; others failed after just a few days. Seven of eight initially responded to clonidine alone (75-950 μg/day) before failing and requiring a second drug. Three received hydromorphone (200-8000 μg/day) and four morphine (0.15-15 mg/day) with clonidine. Four patients then failed 2-drug therapy (duration 6-21 months). Two continue with intrathecal clonidine/hydromorphone (duration 19-29 months) and 1 with clonidine/morphine (duration 21 months). After initiation of intrathecal clonidine, one patient reported good relief with clonidine/morphine until his death 5 months later. In this population, intrathecal clonidine was of limited utility for most patients. It may be of benefit for subset(s) of patients, but in our experience, duration of relief is typically <18 months.

AB - To evaluate the effectiveness of intrathecal clonidine or clonidine/opioid admixture for the treatment of chronic pain states, a retrospective chart audit of 15 patients seen by the Pain Medicine and Neurosurgical Services was performed. Subjects included 9 men and 6 women aged 26-86 years. Diagnoses included complex regional pain syndrome, neuropathic pain, and cancer pain. All patients received a trial of single-shot and/or short-term infusion of clonidine. Those reporting a significant reduction in pain, or at least 50% reduction in their visual analog scale (VAS), received long-term therapy. Intrathecal clonidine as a single-shot dose, infusion, or as intrathecal polytherapy did not improve VAS scales from pre-treatment values in 5 patients. Ten patients reported significant pain relief or >50% decrease in VAS scores with the initial trial and received long-term therapy. Two received clonidine alone for 7-11 months before the therapy failed; others failed after just a few days. Seven of eight initially responded to clonidine alone (75-950 μg/day) before failing and requiring a second drug. Three received hydromorphone (200-8000 μg/day) and four morphine (0.15-15 mg/day) with clonidine. Four patients then failed 2-drug therapy (duration 6-21 months). Two continue with intrathecal clonidine/hydromorphone (duration 19-29 months) and 1 with clonidine/morphine (duration 21 months). After initiation of intrathecal clonidine, one patient reported good relief with clonidine/morphine until his death 5 months later. In this population, intrathecal clonidine was of limited utility for most patients. It may be of benefit for subset(s) of patients, but in our experience, duration of relief is typically <18 months.

KW - Chronic pain

KW - Clonidine

KW - Intrathecal

KW - Opioids

KW - Polyanalgesia

UR - http://www.scopus.com/inward/record.url?scp=0037674939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037674939&partnerID=8YFLogxK

U2 - 10.1016/S0885-3924(03)00144-1

DO - 10.1016/S0885-3924(03)00144-1

M3 - Article

C2 - 12850649

AN - SCOPUS:0037674939

VL - 26

SP - 668

EP - 677

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 1

ER -